Addition Therapeutics

News

Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.

News

Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.